Replies to post #135255 on Biotech Values

[NP1986]

Note too that the two responses were in a specific subset of patients (wild-type extrahepatic cholangiocarcinoma).

Was that expected? It's also only two patients so it would not be prudent to draw conclusions about which types of patients are more likely to respond.

Did gemcitabine + cisplatin actually have CRs in this type of patient population?

The phase III trial had 1 CR in the gemcitabine arm and 1 in the gemcitabine + cisplatin arm (<1% in both arms).
http://www.nejm.org/doi/full/10.1056/NEJMoa0908721#t=articleTop